| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Hypoxanthine |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthine measurement |
Has measured component (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthine overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Accidental aminophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Intentional aminophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline overdose of undetermined intent |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Accidental theophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Intentional theophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline overdose of undetermined intent |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthine measurement |
Component |
True |
Xanthine |
Inferred relationship |
Some |
1 |
| Caffeine and sodium benzoate injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthine adverse reaction |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline adverse reaction |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Choline theophyllinate adverse reaction |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline adverse reaction |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Allergy to xanthine |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Allergy to aminophylline |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Choline theophyllinate allergy |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Allergy to theophylline (finding) |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthine bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing xanthine (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Xanthine |
Inferred relationship |
Some |
1 |
| Caffeine 5mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine citrate 20mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine citrate 20mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/2mg suppository (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin + caffeine + orphenadrine citrate tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing caffeine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Guaifenesin + oxtriphylline 50mg/100mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Guaifenesin + oxtriphylline 50mg/100mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing choline theophyllinate and guaifenesin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing aspirin and butalbital and caffeine and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing caffeine and isometheptene mucate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing aspirin and caffeine and propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing aspirin and caffeine and dihydrocodeine tartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing caffeine and sodium benzoate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aspirin + caffeine + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing butalbital and caffeine and codeine phosphate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing choline theophyllinate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing aspirin and butalbital and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthinol |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Caffeine |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Methyl xanthine |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Uric acid |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Diprophylline |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theobromine |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline (substance) |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline (substance) |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Dimenhydrinate (substance) |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Pentoxifylline (substance) |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Xanthine bronchodilator |
Is a |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Accidental aminophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Intentional aminophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline overdose of undetermined intent |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Accidental theophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Intentional theophylline overdose |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline overdose of undetermined intent |
Causative agent (attribute) |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline 25mg/mL injection solution 10mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline 225mg modified release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline 350mg modified release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline 100mg modified release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Aminophylline 25mg/mL injection solution 10mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 10mg/5mL s/f oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Product containing precisely theophylline monohydrate (as theophylline sodium glycinate) 12 milligram/1 milliliter conventional release oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 175mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 250mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 60mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 125mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 250mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 200mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 300mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
| Theophylline 400mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Xanthine |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.8.8-SNAPSHOT
|
FHIR Version n/a
User: [n/a]